Lexeo Therapeutics, Inc. SEC filings LXEO
Lexeo Therapeutics, Inc. has 361 filings in SEC EDGAR's recent list, going back to Feb 4, 2022. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (acquisition or sale of assets, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Nov 4, 2026 | — |
| S-3 | Shelf registration | Oct 29, 2026 | — |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 22, 2026 | Sep 16, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
May 11, 2026 | May 11, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 30, 2026 | Apr 28, 2026 |
| S-8 | Employee stock plan registration | Mar 30, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Mar 30, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 5, 2026 | Jan 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 27, 2026 | Jan 27, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 12, 2026 | Jan 12, 2026 |
| EFFECT | Filing | Nov 26, 2025 | — |
| 424B3 | Prospectus | Nov 26, 2025 | — |
| CORRESP | Letter to the SEC | Nov 25, 2025 | — |
| S-3 | Shelf registration | Nov 5, 2025 | — |
| S-8 | Employee stock plan registration | Nov 5, 2025 | — |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Material agreement, Results of operations, Unregistered share sale, Other events
|
Oct 17, 2025 | Oct 16, 2025 |
| 424B5 | Prospectus supplement | Oct 17, 2025 | — |
| FWP | Free writing prospectus | Oct 17, 2025 | — |
| 424B5 | Prospectus supplement | Oct 16, 2025 | — |
| FWP | Free writing prospectus | Oct 16, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 7, 2025 | Oct 7, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 14, 2025 | Aug 14, 2025 |
| 424B3 | Prospectus | Jul 1, 2025 | — |
| EFFECT | Filing | Jun 30, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 30, 2025 | Jun 30, 2025 |
| CORRESP | Letter to the SEC | Jun 27, 2025 | — |
| CORRESP | Letter to the SEC | Jun 26, 2025 | — |
| S-3/A | Filing | Jun 26, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2025 | — |
| S-3 | Shelf registration | Jun 13, 2025 | — |
| DEFA14A | Additional proxy material | Jun 5, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 27, 2025 | May 27, 2025 |
| 10-Q/A | Amended quarterly report | May 15, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| ARS | Annual report to shareholders | Apr 28, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 7, 2025 | Apr 7, 2025 |
| S-8 POS | Filing | Mar 24, 2025 | — |
| 424B5 | Prospectus supplement | Mar 24, 2025 | — |
| S-8 | Employee stock plan registration | Mar 24, 2025 | — |
| 10-K | Annual report | Mar 24, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2025 | Mar 24, 2025 |
| 8-K |
Current report
Other events
|
Jan 13, 2025 | Jan 13, 2025 |
| EFFECT | Filing | Dec 19, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Dec 19, 2024 | Dec 18, 2024 |
| CORRESP | Letter to the SEC | Dec 17, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2024 | — |
| S-3 | Shelf registration | Dec 13, 2024 | — |
| EFFECT | Filing | Dec 3, 2024 | — |
| POS AM | Filing | Dec 2, 2024 | — |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 13, 2024 | Nov 11, 2024 |
| 424B3 | Prospectus | Oct 30, 2024 | — |
| 8-K |
Current report
Other events
|
Oct 30, 2024 | Oct 30, 2024 |
| 424B3 | Prospectus | Oct 9, 2024 | — |
| 8-K |
Current report
Other events
|
Oct 9, 2024 | Oct 9, 2024 |
| 424B3 | Prospectus | Aug 12, 2024 | — |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2024 | Aug 12, 2024 |
| 424B3 | Prospectus | Jul 15, 2024 | — |
| 8-K |
Current report
Other events
|
Jul 15, 2024 | Jul 15, 2024 |
| 424B3 | Prospectus | Jul 8, 2024 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 8, 2024 | Jul 8, 2024 |
| 424B3 | Prospectus | Jun 28, 2024 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 28, 2024 | Jun 28, 2024 |
| 424B3 | Prospectus | May 9, 2024 | — |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Dec 31, 2023 |
| 424B3 | Prospectus | Apr 22, 2024 | — |
| 424B3 | Prospectus | Apr 22, 2024 | — |
| 8-K |
Current report
Material agreement, Other events
|
Apr 22, 2024 | Apr 22, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 22, 2024 | Apr 22, 2024 |
| 424B3 | Prospectus | Apr 16, 2024 | — |
| 8-K |
Current report
Other events
|
Apr 16, 2024 | Apr 16, 2024 |
| EFFECT | Filing | Apr 12, 2024 | — |
| 424B3 | Prospectus | Apr 12, 2024 | — |
| CORRESP | Letter to the SEC | Apr 11, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 11, 2024 | — |
| S-1 | Registration statement | Apr 9, 2024 | — |
| 8-K |
Current report
Material agreement, Results of operations, Unregistered share sale, Regulation FD disclosure
|
Mar 11, 2024 | Mar 11, 2024 |
| S-8 | Employee stock plan registration | Mar 11, 2024 | — |
| 10-K | Annual report | Mar 11, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 5, 2024 | Feb 5, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 18, 2023 | Dec 18, 2023 |
| 8-K |
Current report
Results of operations
|
Dec 11, 2023 | Dec 11, 2023 |
| 10-Q | Quarterly report | Dec 11, 2023 | Sep 30, 2023 |
| S-8 | Employee stock plan registration | Nov 7, 2023 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 7, 2023 | Nov 7, 2023 |
| SEC STAFF LETTER | Filing | Nov 6, 2023 | — |
| 424B4 | Prospectus | Nov 6, 2023 | — |
| FWP | Free writing prospectus | Nov 3, 2023 | — |
| EFFECT | Filing | Nov 2, 2023 | — |
| CERT | Filing | Nov 2, 2023 | — |
| CORRESP | Letter to the SEC | Nov 1, 2023 | — |
| S-1/A | Amended registration statement | Nov 1, 2023 | — |
| 8-A12B | Filing | Nov 1, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2023 | — |
| CORRESP | Letter to the SEC | Oct 31, 2023 | — |
| CORRESP | Letter to the SEC | Oct 31, 2023 | — |
| S-1/A | Amended registration statement | Oct 30, 2023 | — |
| CORRESP | Letter to the SEC | Oct 5, 2023 | — |
| S-1 | Registration statement | Sep 29, 2023 | — |
| SEC STAFF LETTER | Filing | Sep 19, 2023 | — |
| DRSLTR | Filing | Sep 18, 2023 | — |
| DRS/A | Filing | Sep 18, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2023 | — |
| DRS/A | Filing | Aug 16, 2023 | — |
| DRSLTR | Filing | Aug 15, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2023 | — |
| DRSLTR | Filing | May 17, 2023 | — |
| DRS/A | Filing | May 17, 2023 | — |
| UPLOAD | Letter from the SEC | May 17, 2022 | — |
| DRSLTR | Filing | May 5, 2022 | — |
| DRS/A | Filing | May 5, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 3, 2022 | — |
| DRS | Filing | Feb 4, 2022 | — |
Showing 136 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LXEO (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1907108
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.